ENETS
Membership Organizations · Germany · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Luisenstr. 58-59, Berlin, Berlin, 10117,...Phone Number
+49 30994045340Website
www.enets.orgRevenue
$10.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About ENETS
ENETS is a leading organization dedicated to enhancing the diagnosis and treatment of neuroendocrine tumors (NETs) since its establishment in 2004. With over 1,500 members from various medical fields, it aims to raise awareness, advance research, and foster collaboration in the NET community. The society offers accredited educational programs, including conferences and webinars, designed for healthcare professionals. ENETS serves a multidisciplinary community that extends beyond Europe, united in the goal of improving NET care and outcomes.Explore more
ENETS Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ENETS your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if ENETS is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at ENETS
Funding: Get notified immidiatlly once ENETS has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on ENETS recently announced quarterly report
Product Launch: Get notified when ENETS launches new products
Click to see if ENETS had a recent Job posting/layoffs
ENETS, which may be a good buyer, showed buying intent in Masked Content Topic
Check if ENETS has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at ENETS
Find 3 more new buyers
Company Profile Activity
Activity Insights
ENETS is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
ENETS is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about ENETS.
ENETS Tech Stack
A closer look at the technologies used by ENETS
ENETS News & Media
ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at European Neuroendocrine Tumor Society (ENETS) Conference
Garching / Munich, February 25 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide topline data results from its Phase 3 COMPETE trial in an oral presentation at the 22nd Annual European Neuroendocrine Tumor Society (ENETS) Conference 2025, held from March 5 – March 7, 2025 in Kraków, Poland.Provectus Biopharmaceuticals Announces Oral Presentation of Updated Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference
KNOXVILLE, TN, March 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of neuroendocrine tumors (NET) metastatic to the liver (mNET) refractory to somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT) (NCT02693067) was presented at the annual conference of the European Neuroendocrine Tumor Society (ENETS), held from March 10-11, 2Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract for Oral Presentation at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference
KNOXVILLE, TN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium), which has completed enrollment for the treatment of neuroendocrine tumors (NET) metastatic to the liver (mNET) refractory to somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT) (NCT02693067), will be presented at the annual conference of the European Neuroendocrine Tumor SocieIpsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide)
PARIS--(BUSINESS WIRE)--Ipsen (Euronext: IPN; ADR: IPSEY) announced today a total of 9 abstracts presenting new data with a focus in NETs.1-10 These include data from the Phase II CLARINET FORTE study and data on the use of independent administration of lanreotide autogel to be presented at the ENETS Conference, taking place virtually 25-27 February 2021.1-3 Updated data from the CLARINET FORTE study were presented including additional quality of life (QoL) data showcasing assessments of patien
Read more news
Top Membership Organizations Companies
Frequently Asked Questions Regarding ENETS
Sign Up For FreeTo access detailed company insights
ENETS is a leading organization dedicated to enhancing the diagnosis and treatment of neuroendocrine tumors (NETs) since its establishment in 2004. With over 1,500 members from various medical fields, it aims to raise awareness, advance research, and foster collaboration in the NET community. The society offers accredited educational programs, incl... Read More
